Skip to main content

Advertisement

Table 4 Frequency of hypoglycemia among study groups

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

  BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 p value
Severe hypoglycemia, n (%) 1 (0.8) 2 (0.9) 0 (0.0) 2 (1.4) 0.54**
Events/patient-year mean (SD) 0.05 (0.6) 0.2 (3.5) 0.0 (0.0) 0.03 (0.3) 0.63*
Symptomatic hypoglycemiaa, n (%) 43 (32.3) 62 (27.9) 43 (25.9) 34 (24.1) 0.46**
Events/patient-year mean (SD) 2.2 (4.4) 2.1 (6.3) 1.8 (4.9) 1.6 (6.7) 0.81*
  1. SD standard deviation
  2. aRequiring blood glucose <60 mg/dL
  3. * Statistical significance of differences was determined by ANOVA
  4. ** Statistical significance of differences was determined by χ2 test